MA52987A - Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak - Google Patents

Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak

Info

Publication number
MA52987A
MA52987A MA052987A MA52987A MA52987A MA 52987 A MA52987 A MA 52987A MA 052987 A MA052987 A MA 052987A MA 52987 A MA52987 A MA 52987A MA 52987 A MA52987 A MA 52987A
Authority
MA
Morocco
Prior art keywords
pyrazin
pyrazolo
derivatives
jak inhibitors
jak
Prior art date
Application number
MA052987A
Other languages
English (en)
Inventor
Matthew Frank Brown
Alpay DERMENCI
Andrew Fensome
Brian Stephen Gerstenberger
Matthew Merrill Hayward
Dafydd Rhys Owen
Stephen Wayne Wright
Li Huang Xing
Xiaojing Yang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA52987A publication Critical patent/MA52987A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052987A 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak MA52987A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662299130P 2016-02-24 2016-02-24

Publications (1)

Publication Number Publication Date
MA52987A true MA52987A (fr) 2021-04-28

Family

ID=58054385

Family Applications (2)

Application Number Title Priority Date Filing Date
MA052987A MA52987A (fr) 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA43668A MA43668B1 (fr) 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA43668A MA43668B1 (fr) 2016-02-24 2017-02-10 Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak

Country Status (44)

Country Link
US (4) US10144738B2 (fr)
EP (2) EP3419978B1 (fr)
JP (1) JP6505956B2 (fr)
KR (1) KR102128671B1 (fr)
CN (1) CN109071546B (fr)
AR (1) AR107714A1 (fr)
AU (1) AU2017222417B2 (fr)
CA (1) CA2958490C (fr)
CL (1) CL2018002358A1 (fr)
CO (1) CO2018008799A2 (fr)
CR (1) CR20180372A (fr)
CU (1) CU24511B1 (fr)
CY (1) CY1122949T1 (fr)
DK (1) DK3419978T3 (fr)
DO (1) DOP2018000187A (fr)
EA (1) EA035036B1 (fr)
EC (1) ECSP18072109A (fr)
ES (1) ES2794779T3 (fr)
GE (1) GEP20217242B (fr)
HR (1) HRP20200781T1 (fr)
HU (1) HUE049305T2 (fr)
IL (1) IL260923B (fr)
LT (1) LT3419978T (fr)
MA (2) MA52987A (fr)
MD (1) MD3419978T2 (fr)
ME (1) ME03743B (fr)
MX (1) MX383747B (fr)
MY (1) MY189118A (fr)
NI (1) NI201800080A (fr)
NZ (1) NZ744349A (fr)
PH (1) PH12018501788A1 (fr)
PL (1) PL3419978T3 (fr)
PT (1) PT3419978T (fr)
RS (1) RS60261B1 (fr)
RU (1) RU2718902C2 (fr)
SG (1) SG11201806307YA (fr)
SI (1) SI3419978T1 (fr)
SV (1) SV2018005726A (fr)
TN (1) TN2018000295A1 (fr)
TW (1) TWI665201B (fr)
UA (1) UA119835C2 (fr)
UY (1) UY37133A (fr)
WO (1) WO2017144995A1 (fr)
ZA (1) ZA201804972B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60261B1 (sr) 2016-02-24 2020-06-30 Pfizer Pirazolo[1,5-a]pirazin-4-il derivativi kao jak-inhibitori
EP3824906A1 (fr) 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
US20190292188A1 (en) 2018-02-27 2019-09-26 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
AR117398A1 (es) 2018-03-12 2021-08-04 Abbvie Inc Inhibidores de la señalización mediada por tirosina cinasa 2
EP3793559A1 (fr) 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Dérivés de dihydropyrazolo pyrazine carboxamide substitués
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
CN113166153B (zh) 2018-07-05 2024-11-01 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
TW202033198A (zh) 2018-10-17 2020-09-16 美商美國禮來大藥廠 以巴瑞克替尼(baricitinib)治療原發性膽汁性膽管炎及原發性硬化性膽管炎
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
BR112021020339A2 (pt) * 2019-04-12 2021-12-07 Primegene Beijing Co Ltd Compostos derivados de pirazolopirazina, composição farmacêutica, e uso dos mesmos
CN114269336A (zh) 2019-04-30 2022-04-01 细胞基因公司 包含阿普斯特和tyk2抑制剂的联合疗法
EP4028007B1 (fr) 2019-09-11 2025-03-26 Pfizer Inc. Traitement de l'hidradénite suppurée avec un inhibiteur de jak
TW202135816A (zh) * 2019-12-18 2021-10-01 美商輝瑞股份有限公司 以激酶抑制劑治療潰瘍性結腸炎
WO2021198980A1 (fr) 2020-04-04 2021-10-07 Pfizer Inc. Procédés de traitement de la maladie à coronavirus 2019
AU2021252213A1 (en) * 2020-04-08 2022-11-03 Pfizer Inc. Crystalline forms of 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutaneacetonitrile, and use thereof
JP2023542298A (ja) * 2020-09-11 2023-10-06 プルモシム セラピューティクス リミテッド ライアビリティ カンパニー 肺高血圧症を治療又は予防する組成物及び方法
CN112592345B (zh) * 2020-12-07 2024-09-13 嘉兴特科罗生物科技有限公司 一种三氮唑并吡嗪类化合物及其用途
TW202241859A (zh) * 2021-01-29 2022-11-01 美商富曼西公司 用於製備５－溴－２－（３－氯－吡啶－２－基）－２ｈ－吡唑－３－甲酸之方法
WO2022165530A1 (fr) * 2021-02-01 2022-08-04 Janssen Biotech, Inc. Inhibiteurs à petites molécules de kinases inductibles par le sel
EP4313055A1 (fr) 2021-03-30 2024-02-07 Pfizer Inc. Méthodes de traitement du vitiligo
CA3236262A1 (fr) 2021-10-25 2023-05-04 Isaac Marx Agents de degradation de tyk2 et leurs utilisations
WO2023083200A1 (fr) * 2021-11-12 2023-05-19 南京明德新药研发有限公司 Composé à cycle condensé pyrazole et son utilisation
WO2024235167A1 (fr) * 2023-05-12 2024-11-21 海南康哲美丽科技有限公司 Composé de pyrazolopyrazine et procédé de préparation d'une forme cristalline de celui-ci
WO2025034912A2 (fr) 2023-08-07 2025-02-13 Cogent Biosciences, Inc. Composés pour inhiber fgfr

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
AR066879A1 (es) * 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
HUE028347T2 (en) 2008-06-10 2016-12-28 Abbvie Inc Tricyclic compounds
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
US8927545B2 (en) 2009-03-30 2015-01-06 Duke University Inhibiting Eph B-3 kinase
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
PH12012502046A1 (en) * 2010-04-14 2017-07-26 Array Biopharma Inc 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
EP2397482A1 (fr) 2010-06-15 2011-12-21 Almirall, S.A. Dérivés d'imidazolone d'hétéroaryle en tant qu'inhibiteurs de JAK
AU2012323399A1 (en) * 2011-10-12 2014-05-29 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
PL2831077T3 (pl) 2012-03-28 2016-10-31 Bicykliczne pochodne pirazynonowe
EP2832734A4 (fr) * 2012-03-28 2015-08-26 Takeda Pharmaceutical Composé hétérocyclique
EP3027601B1 (fr) 2013-07-31 2017-10-25 Gilead Sciences, Inc. Inhibiteurs syk
TW201605811A (zh) 2013-12-11 2016-02-16 阿爾米雷爾有限公司 作為jak抑制劑之吡唑并嘧啶-2基衍生物
US9856263B2 (en) * 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
WO2016009028A1 (fr) 2014-07-17 2016-01-21 Valeo Systèmes d'Essuyage Balai plat caréné d'essuie-glace
PL3227297T3 (pl) * 2014-12-05 2021-10-25 Array Biopharma, Inc. 4,6 podstawione-pyrazolo[1,5-a]pirazyny jako inhibitory kinaz janusowych
TW201639845A (zh) 2015-01-29 2016-11-16 和記黃埔醫藥（上海）有限公司 新的雜芳基和雜環化合物、其組成物及方法
WO2016130920A2 (fr) 2015-02-13 2016-08-18 Dana-Farber Cancer Institute, Inc. Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
GB201504565D0 (en) 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
ES2734048T3 (es) 2015-04-29 2019-12-04 Wuxi Fortune Pharmaceutical Co Ltd Inhibidores de Janus cinasas (JAK)
WO2017108723A2 (fr) 2015-12-22 2017-06-29 F. Hoffmann-La Roche Ag Dérivés pyrazolo [1,5 a]pyrimidine en tant que modulateurs d'irak 4
RS60261B1 (sr) 2016-02-24 2020-06-30 Pfizer Pirazolo[1,5-a]pirazin-4-il derivativi kao jak-inhibitori
WO2018136202A2 (fr) 2016-12-23 2018-07-26 Plexxikon Inc. Composés et procédés pour la modulation de cdk8, et indications associées
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
EP3642201A1 (fr) 2017-06-21 2020-04-29 H. Hoffnabb-La Roche Ag Dérivés d'isoindolinone utilisés en tant que modulateurs d'irak4
EP3668858A1 (fr) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl et dérivés associés

Also Published As

Publication number Publication date
RS60261B1 (sr) 2020-06-30
CN109071546B (zh) 2021-03-02
KR102128671B1 (ko) 2020-06-30
UY37133A (es) 2017-09-29
ME03743B (fr) 2021-04-20
ES2794779T3 (es) 2020-11-19
IL260923B (en) 2022-01-01
MD3419978T2 (ro) 2020-07-31
ZA201804972B (en) 2019-06-26
CA2958490A1 (fr) 2017-08-24
EP3712153A1 (fr) 2020-09-23
EA201891463A1 (ru) 2019-03-29
ECSP18072109A (es) 2018-10-31
AR107714A1 (es) 2018-05-23
NZ744349A (en) 2023-06-30
PL3419978T3 (pl) 2020-11-30
EP3419978B1 (fr) 2020-04-15
CA2958490C (fr) 2024-02-27
CU24511B1 (es) 2021-05-12
CR20180372A (es) 2018-09-19
NI201800080A (es) 2018-11-22
MX383747B (es) 2025-03-14
SV2018005726A (es) 2018-10-24
GEP20217242B (en) 2021-04-12
WO2017144995A1 (fr) 2017-08-31
US20190071448A1 (en) 2019-03-07
AU2017222417A1 (en) 2018-08-02
CN109071546A (zh) 2018-12-21
MX2018010236A (es) 2019-01-14
US10144738B2 (en) 2018-12-04
EP3419978A1 (fr) 2019-01-02
SG11201806307YA (en) 2018-09-27
TWI665201B (zh) 2019-07-11
CO2018008799A2 (es) 2018-09-20
DK3419978T3 (da) 2020-06-02
US12129256B2 (en) 2024-10-29
AU2017222417B2 (en) 2020-07-09
TW201741313A (zh) 2017-12-01
RU2018130547A3 (fr) 2020-03-25
MA43668B1 (fr) 2020-05-29
RU2718902C2 (ru) 2020-04-15
SI3419978T1 (sl) 2020-08-31
CY1122949T1 (el) 2021-10-29
JP2019510003A (ja) 2019-04-11
BR112018015501A2 (pt) 2018-12-18
CU20180078A7 (es) 2019-02-04
US20200399281A1 (en) 2020-12-24
HRP20200781T1 (hr) 2020-07-24
CL2018002358A1 (es) 2018-11-30
US11472809B2 (en) 2022-10-18
PH12018501788A1 (en) 2019-06-17
PT3419978T (pt) 2020-06-01
DOP2018000187A (es) 2019-01-31
US20170240552A1 (en) 2017-08-24
HK1258157A1 (zh) 2019-11-08
UA119835C2 (uk) 2019-08-12
KR20180103158A (ko) 2018-09-18
JP6505956B2 (ja) 2019-04-24
RU2018130547A (ru) 2020-03-25
EA035036B1 (ru) 2020-04-20
HUE049305T2 (hu) 2020-09-28
MY189118A (en) 2022-01-26
LT3419978T (lt) 2020-06-10
US20230045252A1 (en) 2023-02-09
EP3712153B1 (fr) 2021-12-01
TN2018000295A1 (en) 2020-01-16
US10822341B2 (en) 2020-11-03

Similar Documents

Publication Publication Date Title
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
IL266305B (en) History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
DK3478682T3 (da) [1,2,4]triazolo[1,5-a]pyridinylsubstituerede indolforbindelser
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
DK3418281T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er anvendelige som inhibitorer af atr-kinase til behandling af cancersygdomme
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
HUE053643T2 (hu) (S)-N-(5 -((R)-2-(2,5-difluor-fenil)-pirrolidin-1-il)-pirazolo[1,5-A] pirimidin-3-il)-3-hidroxi-pirrolidin-1-karboxamid elõkészítése
ME03672B (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
EP3380475A4 (fr) Dérivés d'octahydropyrrolo [3, 4-c
MA46690A (fr) Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
EP3508487A4 (fr) COMPOSÉ DE PYRAZOLO [1,5-a]PYRIMIDINE
IL290419B (en) Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta
EP3096762C0 (fr) Pyrazolo[1,5-a]pyrimidines comme composés antiviraux
EP3679042A4 (fr) Dérivés d'imidazo[1,5-a]pyrazine en tant qu'inhibiteurs de pi3kdelta
IL258070A (en) Cyclic ether history of pyrazolo[5,1-a]pyrimidine-3-carboxamide
HUE052997T2 (hu) JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok
MA46463A (fr) Composés de pyrazolo[1,5-a]pyridine substitués en tant qu'inhibiteurs de la kinase ret
TH1601003657A (th) อนุพันธ์ [1,2,4] ไตรอะโซโล [1,5-a]ไพริมิดีน ดังสารยับยั้งโปรเตียโซมของ โปรโตซัวสำหรับการรักษาของโรคที่เกิดจากปรสิต เช่น โรคลิชมาเนียซิส